Inner Mongolia Furui Medical Science Co., Ltd. Class A

Inner Mongolia Furui Medical Science Co., Ltd. Class A

SSZSE:300049
40.33
CNY
-1.48
(-3.54%)
1.19EPS
70.56P/E
12.44BMarket Cap
Apr 29Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.13
5.18
2.31
3.14
3.1
3.18
3.25
3.15
3.46
3.83
4.39
5.12
6.01
6.21
Basic EPS, GAAP
0.02
0.7
0.35
0.46
0.23
0.13
0.17
0.24
0.37
0.37
0.39
0.43
0.58
0.67
Free Cash Flow per Basic Share
-0.85
-0.26
0.12
-0.25
0.35
-0.06
0.74
0.35
0.55
0.38
0.44
0.01
0.61
- -
Dividend per Share
0.01
0.03
0.11
0.11
0.12
0.11
0.01
0.01
0.01
0.27
0.2
0.01
0.01
0.08
Book Value per Share
2.85
3.22
5.09
5.56
5.68
5.07
5.01
5.14
5.78
5.87
5.88
6.56
7.47
7.54
Tangible Book Value per Share
2.09
2.15
3.98
4.31
3.91
3.26
2.83
2.98
3.68
3.77
3.69
3.7
4.59
4.62
Basic Weighted Avg Shares
245
125
262
263
266
272
256
256
260
263
263
263
266
264
Sales/Revenue/Turnover
523
646
604
827
823
867
832
808
898
1,009
1,154
1,349
1,595
1,636
Operating Margin (%)
3.96
19.63
19.69
21.28
18.79
15.59
16.52
18.08
19.67
18.37
21
22.89
25.03
25.59
Depreciation Expense
16
41
22
35
46
44
51
69
67
72
81
91
101
- -
Net Income, GAAP
5
87
92
121
61
35
43
62
95
98
102
113
154
176
Effective Tax Rate (%)
88.2
30.39
18.44
20.74
47.17
61.11
20.94
20.81
21.73
24.12
24.76
27.6
26.28
24.98
Profit Margin (%)
0.94
13.51
15.17
14.64
7.42
4.08
5.22
7.67
10.63
9.7
8.8
8.4
9.66
10.76
Working Capital
310
414
1,085
1,025
1,018
645
702
743
870
994
956
1,154
1,062
1,075
LT Debt
6
- -
- -
- -
10
9
69
55
54
42
45
55
69
112
Total Equity
749
915
1,651
1,825
1,916
1,514
1,552
1,616
1,806
1,826
1,847
2,128
2,472
2,530
Return on Invested Capital (%)
0.25
9.4
7.13
7.99
3.74
2.67
6.14
5.52
7.99
7.59
10
9.77
11.2
12.84
Return on Capital (%)
1.01
10.11
6.59
5.27
2.74
1.53
-0.68
2.12
2.45
2.72
1.41
1.59
2.15
1.67
Return on Common Equity (%)
0.69
11.26
8.43
8.64
4.13
2.5
3.27
4.64
6.65
6.39
6.57
6.88
8.27
9.22

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
103
132
131
LT Borrowings
10
44
45
LT Finance Leases
70
73
67
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
265
264
264
Market Capitalization
15,342
10,264
12,437

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,519
1,487
1,511
Cash, Cash Equivalents & STI
749
738
740
Accounts Receivable, Net
389
359
400
Inventories
150
146
152
Total Current Liabilities
442
469
436
Payables & Accruals
- -
- -
- -
ST Debt
103
132
131
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.66%
9.08%
16.15%
Free Cash Flow
446.29%
1,300.31%
6,555.08%
Net Income, GAAP
11.37%
21.61%
36.02%
Sales/Revenue/Turnover
10.79%
14.62%
18.26%
Total Cash Common Dividend
334.45%
680.28%
3.87%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
323
320
337
369
1,349
2025
330
383
- -
494
1,595
2026
360
395
387
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.16
0.12
0.1
0.04
0.43
2025
0.11
0.09
- -
0.16
0.58
2026
0.12
0.12
0.27
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
0.15
-0.15
0.01
2025
- -
- -
- -
-0.08
0.01
2026
- -
- -
0.15
- -
- -

Company Description

CEO
Guan Yi Wang
Full Time Employees
964
Sector
Health technology
Industry
Medical specialties
Address
Central Tower, Zhonghai Plaza Beijing BE China 100020
IPO Date
Jan 21, 2010
Website
fu-rui.com
Business
Inner Mongolia Furui Medical Science Co., Ltd. (300049.SZ) engages in the research, development, production, and sale of pharmaceuticals, diagnostic equipment, and medical services focused on liver disease prevention, diagnosis, and treatment in China and internationally; its core products and services include Compound Turtle and Soft Liver Tablets for hepatology treatment, the FibroScan series of liver fibrosis diagnostic instruments, digital health management platforms, prescription drugs, and health management center services targeting chronic liver conditions such as fibrosis, hepatitis, and fatty liver disease. The company operates through two primary segments, pharmaceutical production and sales alongside diagnostic equipment research, development, production, and sales, with subsidiaries and operations extending to France, the United States, Germany, Spain, the United Kingdom, Italy, Singapore, Hong Kong, and other regions; founded in 1998 and headquartered in Beijing, China, it lists on the Shenzhen Stock Exchange GEM and maintains a workforce of approximately 867 employees serving hospitals, clinics, and patients globally. In recent developments, the company pursues strategic expansion through an equity acquisition framework agreement to acquire a 96.20% stake in Chengdu Furuihui Hospital Management Co., enhancing its medical services capabilities, while continuing partnerships with healthcare institutions and emphasizing digital transformation and international compliance certifications like ISO 13485 and CE marking amid steady revenue growth from equipment and pharmaceutical divisions.